BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
2.070
+0.055 (2.73%)
At close: May 26, 2026, 4:00 PM EDT
2.150
+0.080 (3.86%)
After-hours: May 26, 2026, 6:16 PM EDT
BioNexus Gene Lab Employees
BioNexus Gene Lab had 19 employees as of December 31, 2025. The number of employees decreased by 13 or -40.63% compared to the previous year.
Employees
19
Change (1Y)
-13
Growth (1Y)
-40.63%
Revenue / Employee
$279,509
Profits / Employee
-$152,887
Market Cap
5.00M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 19 | -13 | -40.63% | 19 | 0 |
| Dec 31, 2024 | 32 | 2 | 6.67% | 32 | 0 |
| Dec 31, 2023 | 30 | -3 | -9.09% | 30 | 0 |
| Dec 31, 2022 | 33 | 1 | 3.13% | 27 | 6 |
| Dec 31, 2021 | 32 | -75 | -70.09% | 27 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Core Molding Technologies | 1,239 |
| FutureFuel | 493 |
| Northern Technologies International | 272 |
| Aemetis | 220 |
| Bon Natural Life | 96 |
| Flexible Solutions International | 78 |
| J-Star Holding | 65 |
| Loop Industries | 40 |
BGLC News
- 2 months ago - Bionexus Gene Lab appoints Muthu Meyyappan as CCO, Fidelion - TheFly
- 2 months ago - BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform - GlobeNewsWire
- 3 months ago - Bionexus Gene Lab appoints Matthew Barsing as Chairman - TheFly
- 3 months ago - BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman - GlobeNewsWire
- 4 months ago - Bionexus Gene Lab announces formal commencement of 2026 Deployment Phase - TheFly
- 4 months ago - BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market - GlobeNewsWire
- 6 months ago - Bionexus Gene Lab completes investment in Fidelion Diagnostics - TheFly
- 6 months ago - BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™ - GlobeNewsWire